(Reuters) -Gilead Sciences Inc said on Friday it was stopping a late-stage trial of its blood cancer combination treatment following an analysis that showed it would not be effective.
The company was studying antibody magrolimab in combination with a type of chemotherapy called azacitidine for the treatment of patients with a higher risk of Myelodysplastic syndromes (MDS), a rare group of bone marrow failure disorders.
Gilead, whose shares dropped over 1% in after-market trading, recommended that treatment with magrolimab in patients with MDS should be stopped.
(Reporting by Sriparna Roy in BengaluruEditing by Vinay Dwivedi)
